The Filings Report

Medpace Holdings, Inc. Common Stock

MEDPNasdaqCIK 1668397Healthcare / Diagnostics & Researchfiscal year ends December47 quarters since 2015

Revenue, Q3 FY2026
$716M
+8.5% on Q3 FY2025
Net income
$137M
+23.7% on Q3 FY2025
Free cash flow
$196M
−16.6% on Q3 FY2025
Diluted EPS
$4.84
+25.4% on Q3 FY2025
Revenue, TTM
$2.8B
trailing four quarters
Net margin, TTM
18.2%
net income $518M
Free cash flow, TTM
$668M
$723M less $55M capex
Cash and equivalents
$705M
long-term debt —, Sep 30, 2026
Shares, 12-month change
−0.7%
28M shares, Sep 30, 2026
Buybacks, TTM
$295M
1.6% of market value
Dividends, TTM
—
no yield
Market value
$18.2B
at the close, buybacks

Latest quarter Q3 FY2026, filed October 22, 2026. Trailing figures sum the latest four quarters. Market values at the latest close, from a market data vendor.

In Q3 FY2026, the quarter ended September 30, 2026, Medpace Holdings, Inc. Common Stock reported revenue of $716M, +8.5% on Q3 FY2025, and net income of $137M (+23.7%). Operating margin was 23.1%. Free cash flow, operating cash flow less capital expenditures, was $196M ($217M less $20M). Diluted earnings per share were $4.84.

The last 16 quarters

Q4 FY2022 to Q3 FY2026, through the filing of October 22, 2026.

Revenue and net incomeRevenueNet income
$0$200M$400M$600M$800MQ4'22, Revenue: $394MQ4'22, Net income: $69MQ4'22Q1'23, Revenue: $434MQ1'23, Net income: $73MQ1'23Q2'23, Revenue: $461MQ2'23, Net income: $61MQ2'23Q3'23, Revenue: $492MQ3'23, Net income: $71MQ3'23Q4'23, Revenue: $498MQ4'23, Net income: $78MQ4'23Q1'24, Revenue: $511MQ1'24, Net income: $103MQ1'24Q2'24, Revenue: $528MQ2'24, Net income: $88MQ2'24Q3'24, Revenue: $533MQ3'24, Net income: $96MQ3'24Q4'24, Revenue: $537MQ4'24, Net income: $117MQ4'24Q1'25, Revenue: $559MQ1'25, Net income: $115MQ1'25Q2'25, Revenue: $603MQ2'25, Net income: $90MQ2'25Q3'25, Revenue: $660MQ3'25, Net income: $111MQ3'25Q4'25, Revenue: $708MQ4'25, Net income: $135MQ4'25Q1'26, Revenue: $707MQ1'26, Net income: $124MQ1'26Q2'26, Revenue: $707MQ2'26, Net income: $121MQ2'26Q3'26, Revenue: $716MQ3'26, Net income: $137MQ3'26$0$200M$400M$600M$800MQ4'22, Revenue: $394MQ4'22, Net income: $69MQ1'23, Revenue: $434MQ1'23, Net income: $73MQ1'23Q2'23, Revenue: $461MQ2'23, Net income: $61MQ3'23, Revenue: $492MQ3'23, Net income: $71MQ3'23Q4'23, Revenue: $498MQ4'23, Net income: $78MQ1'24, Revenue: $511MQ1'24, Net income: $103MQ1'24Q2'24, Revenue: $528MQ2'24, Net income: $88MQ3'24, Revenue: $533MQ3'24, Net income: $96MQ3'24Q4'24, Revenue: $537MQ4'24, Net income: $117MQ1'25, Revenue: $559MQ1'25, Net income: $115MQ1'25Q2'25, Revenue: $603MQ2'25, Net income: $90MQ3'25, Revenue: $660MQ3'25, Net income: $111MQ3'25Q4'25, Revenue: $708MQ4'25, Net income: $135MQ1'26, Revenue: $707MQ1'26, Net income: $124MQ1'26Q2'26, Revenue: $707MQ2'26, Net income: $121MQ3'26, Revenue: $716MQ3'26, Net income: $137MQ3'26

Net income losses drawn in red.

Free cash flow
$0$100M$200M$300MQ4'22, Free cash flow: $127MQ4'22Q1'23, Free cash flow: $71MQ1'23Q2'23, Free cash flow: $74MQ2'23Q3'23, Free cash flow: $106MQ3'23Q4'23, Free cash flow: $146MQ4'23Q1'24, Free cash flow: $147MQ1'24Q2'24, Free cash flow: $104MQ2'24Q3'24, Free cash flow: $139MQ3'24Q4'24, Free cash flow: $183MQ4'24Q1'25, Free cash flow: $116MQ1'25Q2'25, Free cash flow: $142MQ2'25Q3'25, Free cash flow: $235MQ3'25Q4'25, Free cash flow: $188MQ4'25Q1'26, Free cash flow: $145MQ1'26Q2'26, Free cash flow: $138MQ2'26Q3'26, Free cash flow: $196MQ3'26$0$100M$200M$300MQ4'22, Free cash flow: $127MQ1'23, Free cash flow: $71MQ1'23Q2'23, Free cash flow: $74MQ3'23, Free cash flow: $106MQ3'23Q4'23, Free cash flow: $146MQ1'24, Free cash flow: $147MQ1'24Q2'24, Free cash flow: $104MQ3'24, Free cash flow: $139MQ3'24Q4'24, Free cash flow: $183MQ1'25, Free cash flow: $116MQ1'25Q2'25, Free cash flow: $142MQ3'25, Free cash flow: $235MQ3'25Q4'25, Free cash flow: $188MQ1'26, Free cash flow: $145MQ1'26Q2'26, Free cash flow: $138MQ3'26, Free cash flow: $196MQ3'26

Operating cash flow less capital expenditures; negative quarters in red.

Cash and equivalents against long-term debtCash and equivalentsLong-term debt
$0$200M$400M$600M$800MQ4'22, Cash and equivalents: $28MQ4'22Q1'23, Cash and equivalents: $47MQ1'23Q2'23, Cash and equivalents: $39MQ2'23Q3'23, Cash and equivalents: $95MQ3'23Q4'23, Cash and equivalents: $245MQ4'23Q1'24, Cash and equivalents: $407MQ1'24Q2'24, Cash and equivalents: $511MQ2'24Q3'24, Cash and equivalents: $657MQ3'24Q4'24, Cash and equivalents: $669MQ4'24Q1'25, Cash and equivalents: $441MQ1'25Q2'25, Cash and equivalents: $46MQ2'25Q3'25, Cash and equivalents: $285MQ3'25Q4'25, Cash and equivalents: $497MQ4'25Q1'26, Cash and equivalents: $653MQ1'26Q2'26, Cash and equivalents: $503MQ2'26Q3'26, Cash and equivalents: $705MQ3'26$0$200M$400M$600M$800MQ4'22, Cash and equivalents: $28MQ1'23, Cash and equivalents: $47MQ1'23Q2'23, Cash and equivalents: $39MQ3'23, Cash and equivalents: $95MQ3'23Q4'23, Cash and equivalents: $245MQ1'24, Cash and equivalents: $407MQ1'24Q2'24, Cash and equivalents: $511MQ3'24, Cash and equivalents: $657MQ3'24Q4'24, Cash and equivalents: $669MQ1'25, Cash and equivalents: $441MQ1'25Q2'25, Cash and equivalents: $46MQ3'25, Cash and equivalents: $285MQ3'25Q4'25, Cash and equivalents: $497MQ1'26, Cash and equivalents: $653MQ1'26Q2'26, Cash and equivalents: $503MQ3'26, Cash and equivalents: $705MQ3'26

Positions at each quarter end, as filed; short-term investments are not included.

Income statement

Last eight quarters, newest first, through Q3 FY2026 filed October 22, 2026.

Medpace Holdings, Inc. Common Stock income statement, quarterly
Millions of dollarsQ3 FY2026ended Sep 30, 2026filed Oct 22, 2026Q2 FY2026ended Jun 30, 2026filed Jul 23, 2026Q1 FY2026ended Mar 31, 2026filed Apr 23, 2026Q4 FY2025ended Dec 31, 2025filed Feb 10, 2026Q3 FY2025ended Sep 30, 2025filed Oct 23, 2025Q2 FY2025ended Jun 30, 2025filed Jul 22, 2025Q1 FY2025ended Mar 31, 2025filed Apr 22, 2025Q4 FY2024ended Dec 31, 2024filed Feb 11, 2025YoYQ3 FY2026vs Q3 FY2025
Revenue716707707708660603559537+8.5%
Cost of revenue—————————
Gross profit—————————
Research and development—————————
Selling, general and administrative5248484548475845+7.7%
Operating income166147142153142126114125+16.7%
Other income (expense)55641(2)59+422.0%
Pretax income171152148157143125118134+19.7%
Income tax333024223234417+5.5%
Net income13712112413511190115117+23.7%
Diluted EPS ($)4.844.254.28—3.863.103.67—+25.4%
Diluted shares (millions)282929—292931——

Fourth quarters are the fiscal year less the first nine months when the filer reports no discrete fourth quarter, and are marked. Diluted EPS is never derived, so a derived quarter shows none. Italic figures are derived.

Balance sheet

Last eight quarters, newest first, through Q3 FY2026 filed October 22, 2026.

Medpace Holdings, Inc. Common Stock balance sheet, quarterly
Millions of dollarsQ3 FY2026ended Sep 30, 2026filed Oct 22, 2026Q2 FY2026ended Jun 30, 2026filed Jul 23, 2026Q1 FY2026ended Mar 31, 2026filed Apr 23, 2026Q4 FY2025ended Dec 31, 2025filed Feb 10, 2026Q3 FY2025ended Sep 30, 2025filed Oct 23, 2025Q2 FY2025ended Jun 30, 2025filed Jul 22, 2025Q1 FY2025ended Mar 31, 2025filed Apr 22, 2025Q4 FY2024ended Dec 31, 2024filed Feb 11, 2025YoYQ3 FY2026vs Q3 FY2025
Cash and equivalents70550365349728546441669+147.2%
Short-term investments—————————
Total current assets1,2451,0501,1399907375218211,029+68.9%
Total assets2,3032,0572,1301,9751,7531,5721,8972,101+31.4%
Total current liabilities1,4961,4351,3451,3441,2841,2201,1221,105+16.5%
Long-term debt—————————
Total liabilities1,7181,6231,5311,5161,4591,3991,3041,275+17.7%
Stockholders’ equity585434598459294172594826+99.2%
Shares outstanding (millions)2828292828282930—

Positions at each period end. Nothing on this statement is derived. Long-term debt is the filed noncurrent line only; no total-debt composite is constructed across filers. Italic figures are derived.

Cash flow statement

Last eight quarters, newest first, through Q3 FY2026 filed October 22, 2026.

Medpace Holdings, Inc. Common Stock cash flow statement, quarterly
Millions of dollarsQ3 FY2026ended Sep 30, 2026filed Oct 22, 2026Q2 FY2026ended Jun 30, 2026filed Jul 23, 2026Q1 FY2026ended Mar 31, 2026filed Apr 23, 2026Q4 FY2025ended Dec 31, 2025filed Feb 10, 2026Q3 FY2025ended Sep 30, 2025filed Oct 23, 2025Q2 FY2025ended Jun 30, 2025filed Jul 22, 2025Q1 FY2025ended Mar 31, 2025filed Apr 22, 2025Q4 FY2024ended Dec 31, 2024filed Feb 11, 2025YoYQ3 FY2026vs Q3 FY2025
Operating cash flow217162152193246149126191−12.0%
Capital expenditures202475116108+88.2%
Free cash flow (CFO − capex)196138145188235142116183−16.6%
Depreciation and amortization—————————
Share repurchases0295005541372170−100.0%
Dividends paid—————————

10-Qs file cash flows as year-to-date totals, so quarterly figures are differenced from consecutive filings and marked. Free cash flow is operating cash flow less capital expenditures, computed from the two filed lines. Italic figures are derived.

Annual statements

Every fiscal year filed, newest first, through FY2025 filed February 10, 2026.

Income statement

Medpace Holdings, Inc. Common Stock income statement, annual
Millions of dollarsFY2025ended Dec 31, 2025filed Feb 10, 2026FY2024ended Dec 31, 2024filed Feb 11, 2025FY2023ended Dec 31, 2023filed Feb 13, 2024FY2022ended Dec 31, 2022filed Feb 14, 2023FY2021ended Dec 31, 2021filed Feb 15, 2022FY2020ended Dec 31, 2020filed Feb 16, 2021FY2019ended Dec 31, 2019filed Feb 25, 2020FY2018ended Dec 31, 2018filed Feb 26, 2019FY2017ended Dec 31, 2017filed Feb 27, 2018FY2016ended Dec 31, 2016filed Feb 28, 2017FY2015ended Dec 31, 2015filed Nov 3, 2016
Revenue2,5302,1091,8861,4601,142926861705436422359
Cost of revenue———————————
Gross profit———————————
Research and development———————————
Selling, general and administrative198180161131108929576636257
Operating income535447337279199167127101655221
Other income (expense)729(1)431(2)(7)(8)(31)(28)
Pretax income542476336283202169125945722(8)
Income tax91725337202324211891
Net income451404283245182145100733913(9)
Diluted EPS ($)15.2812.638.887.284.813.842.671.970.980.37(0.28)
Diluted shares (millions)3032323438383837403631

Balance sheet

Medpace Holdings, Inc. Common Stock balance sheet, annual
Millions of dollarsFY2025ended Dec 31, 2025filed Feb 10, 2026FY2024ended Dec 31, 2024filed Feb 11, 2025FY2023ended Dec 31, 2023filed Feb 13, 2024FY2022ended Dec 31, 2022filed Feb 14, 2023FY2021ended Dec 31, 2021filed Feb 15, 2022FY2020ended Dec 31, 2020filed Feb 16, 2021FY2019ended Dec 31, 2019filed Feb 25, 2020FY2018ended Dec 31, 2018filed Feb 26, 2019FY2017ended Dec 31, 2017filed Feb 27, 2018FY2016ended Dec 31, 2016filed Feb 28, 2017FY2015ended Dec 31, 2015filed Nov 3, 2016
Cash and equivalents4976692452846127813223263715
Short-term investments———————————
Total current assets9901,02959433469147431717813013395
Total assets1,9752,1011,6571,3521,6601,3911,1431,005951979984
Total current liabilities1,3441,105925803557440343263193169134
Long-term debt——————080205151378
Total liabilities1,5161,2751,098966707585417406447368571
Stockholders’ equity459826559386953806726599509611413
Shares outstanding (millions)28303131353636363541—

Cash flow statement

Medpace Holdings, Inc. Common Stock cash flow statement, annual
Millions of dollarsFY2025ended Dec 31, 2025filed Feb 10, 2026FY2024ended Dec 31, 2024filed Feb 11, 2025FY2023ended Dec 31, 2023filed Feb 13, 2024FY2022ended Dec 31, 2022filed Feb 14, 2023FY2021ended Dec 31, 2021filed Feb 15, 2022FY2020ended Dec 31, 2020filed Feb 16, 2021FY2019ended Dec 31, 2019filed Feb 25, 2020FY2018ended Dec 31, 2018filed Feb 26, 2019FY2017ended Dec 31, 2017filed Feb 27, 2018FY2016ended Dec 31, 2016filed Feb 28, 2017FY2015ended Dec 31, 2015filed Nov 3, 2016
Operating cash flow7136094333882632592021579792—
Capital expenditures313737372831181612146
Free cash flow (CFO − capex)6825723973512352271841418678—
Depreciation and amortization———————————
Share repurchases91717014484862980015600
Dividends paid———————————

Insider activity

Form 4 filings by officers, directors and 10% owners, November 1, 2024 to November 1, 2026. Only open-market purchases and sales count as buys and sells; awards, exercises, tax withholding and gifts are listed in grey and never counted.

Bought, three months
$0
0 purchases by 0 insiders; officers and directors $0
Sold, three months
$213M
30 sales by 7 insiders; officers and directors $213M
Bought, twelve months
$0
0 purchases by 0 insiders; officers and directors $0
Sold, twelve months
$453M
55 sales by 9 insiders; officers and directors $453M

The last 25 transactions

TradedInsiderRoleTransactionSharesPriceValueHeld afterFiled
Oct 27, 2026Burwig Susan EExec. VP, Operationsopen-market sale3,940$677.00$3M54,012Oct 28, 2026
Oct 26, 2026Burwig Susan EExec. VP, Operationsopen-market sale16,060$677.00$11M57,624Oct 28, 2026
Oct 26, 2026Burwig Susan EExec. VP, Operationsoption exercise328$166.73$55K57,952Oct 28, 2026
Oct 21, 2026Burwig Susan EExec. VP, Operationsoption exercise2,700$166.73$450K73,684Oct 23, 2026
Oct 12, 2026Burwig Susan EExec. VP, Operationsoption exercise3,000$166.73$500K70,984Oct 14, 2026
Oct 7, 2026Burwig Susan EExec. VP, Operationsoption exercise2,000$166.73$333K67,984Oct 9, 2026
Sep 30, 2026McCarthy Cornelius P. IIIDirectoroption exercise28——12,303Oct 2, 2026
Sep 30, 2026Kraft Robert O.Directoroption exercise32——987Oct 2, 2026
Sep 30, 2026Carley Brian TDirectoroption exercise36——27,861Oct 2, 2026
Sep 30, 2026Troendle August J.President & CEO, Director, 10% owneropen-market sale21,966$625.47$14M338,225Oct 1, 2026
Sep 29, 2026Troendle August J.President & CEO, Director, 10% owneropen-market sale26,701$621.02$17M360,191Oct 1, 2026
Sep 28, 2026Troendle August J.President & CEO, Director, 10% owneropen-market sale2,410$620.07$1M386,892Sep 29, 2026
Sep 25, 2026Troendle August J.President & CEO, Director, 10% owneropen-market sale154$620.60$96K389,302Sep 29, 2026
Sep 24, 2026Troendle August J.President & CEO, Director, 10% owneropen-market sale27,833$621.33$17M389,456Sep 25, 2026
Sep 23, 2026Troendle August J.President & CEO, Director, 10% owneropen-market sale16,083$628.64$10M417,289Sep 25, 2026
Sep 22, 2026Troendle August J.President & CEO, Director, 10% owneropen-market sale49,018$628.11$31M433,372Sep 23, 2026
Sep 21, 2026Troendle August J.President & CEO, Director, 10% owneropen-market sale21,883$623.29$14M482,390Sep 23, 2026
Sep 17, 2026Troendle August J.President & CEO, Director, 10% owneropen-market sale10,880$620.40$7M504,273Sep 21, 2026
Sep 16, 2026Troendle August J.President & CEO, Director, 10% owneropen-market sale8,770$621.29$5M515,153Sep 17, 2026
Sep 15, 2026Troendle August J.President & CEO, Director, 10% owneropen-market sale15,971$620.84$10M523,923Sep 17, 2026
Sep 15, 2026Burwig Susan EExec. VP, Operationsoption exercise3,000$166.73$500K65,984Sep 17, 2026
Aug 27, 2026Troendle August J.President & CEO, Director, 10% owneropen-market sale650$620.27$403K539,894Aug 31, 2026
Aug 26, 2026Kraft Robert O.Directoroption exercise3,858$84.36$325K4,813Aug 28, 2026
Aug 26, 2026Kraft Robert O.Directoropen-market sale3,858$617.81$2M955Aug 28, 2026
Aug 26, 2026Troendle August J.President & CEO, Director, 10% owneropen-market sale4,000$620.03$2M540,544Aug 27, 2026

Full insider history for Medpace Holdings, Inc. Common Stock, or insider activity across all companies. A record of filings, not a recommendation.

Tracked funds holding it

1 of the tracked managers held MEDP in their latest 13F filing, through August 14, 2026. Weight is the share of the fund’s reported portfolio. How the funds have traded MEDP by quarter.

FundManagerQuarterValueSharesWeightMove
FundsmithTerry SmithQ2 2026$28M52,3720.20%trimmed −16.4%

Sources

Fiscal year ends in month 12; periods are labeled with the issuer's own fiscal calendar. Values are as most recently filed (restatements apply; per-share values are on current split basis per the connector's split table, flagged in adjusted). Flow items flagged in `derived` were computed (Q4 = FY − nine months; quarterly cash flow differenced from year-to-date filings) rather than read from a filing. `reconciliation.repaired` lists periods where a full-year figure was filed in a quarter slot: that row was dropped and the quarter rebuilt from the annual figure. `reconciliation.quarantined` lists periods where four filed quarters do not sum to the filed year — those quarterly values are withheld, so a blank there is a withholding rather than an absence of reporting.

Filer
Medpace Holdings, Inc., CIK 1668397 on EDGAR
Extract generated
November 1, 2026
Withheld
none
Repaired
2 quarters where a full-year figure was filed in a quarter slot and the quarter was rebuilt: other income FY2022, other income FY2023
XBRL concepts behind each line

Income statement

Revenue: RevenueFromContractWithCustomerExcludingAssessedTax, SalesRevenueNet
Cost of revenue: not filed
Gross profit: not filed
Research and development: not filed
Selling, general and administrative: SellingGeneralAndAdministrativeExpense
Operating income: OperatingIncomeLoss
Other income (expense): NonoperatingIncomeExpense
Pretax income: IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
Income tax: IncomeTaxExpenseBenefit
Net income: NetIncomeLoss
Diluted EPS ($): EarningsPerShareDiluted
Diluted shares (millions): WeightedAverageNumberOfDilutedSharesOutstanding

Balance sheet

Cash and equivalents: CashAndCashEquivalentsAtCarryingValue
Short-term investments: not filed
Total current assets: AssetsCurrent
Total assets: Assets
Total current liabilities: LiabilitiesCurrent
Long-term debt: LongTermDebtNoncurrent
Total liabilities: Liabilities
Stockholders’ equity: StockholdersEquity
Shares outstanding (millions): dei:EntityCommonStockSharesOutstanding

Cash flow statement

Operating cash flow: NetCashProvidedByUsedInOperatingActivities
Capital expenditures: PaymentsToAcquirePropertyPlantAndEquipment
Free cash flow (CFO − capex): not filed
Depreciation and amortization: not filed
Share repurchases: PaymentsForRepurchaseOfCommonStock
Dividends paid: not filed

The data

The statements on this page as files, generated November 1, 2026.

JSON file
/data/financials/MEDP.json